Amisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Despite the effectiveness of clomipramine and selective serotonin reuptake inhibitors (SSRIs) in the treatment of obsessive–compulsive disorder (OCD), 40% to 60% of patients who receive an adequate treatment with these agents have significant persisting symptoms. Newer atypical antipsychotic drugs showed efficacy as augmenting agents in patients with OCD resistant to serotonin reuptake inhibitors (SRIs). The objective of this study was to evaluate the efficacy and safety of amisulpiride augmentation in treatment resistant OCD. A total of 20 patients diagnosed with OCD according to DSM‐IV criteria and having a history of resistance to treatment with SRIs were included in the study. Amisulpiride 200 mg/day was added to ongoing SRI treatment and titrated up to 600 mg/day in flexible doses. The mean amisulpiride dose was 325 ± 106 mg/day. The patients were assessed with the Yale‐Brown obsessive‐compulsive scale (Y‐BOCS) at baseline and at week 12 of amisulpiride treatment. Side effects were monitored by the UKU side effect rating scale. The reduction in Y‐BOCS scores between the baseline (26.7 ± 6.3) and the end of the treatment (12.5 ± 2.8) was statistically significant (p = 0.0001). The most commonly observed side effects included weight gain (14 patients, 70%), mild sedation (13 patients, 65%) and asthenia (7 patients, 35%). This study has several limitations and, hence, the results are preliminary and require confirmation in a randomized controlled trial. In conclusion, this study suggests that amisulpiride may be a promising option as an augmentation strategy in treatment resistant OCD. Copyright © 2003 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571 · cited 2×
“, 2002), 50%–85% for risperidone (Jacobsen, 1995; McDougle et al., 2000) and 43.”
BackgroundInfluential5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370 · cited 1×
“Clozapine, olanzapine, quetiapine and risperidone induce a high 5HT2 receptor antagonism, whereas relatively higher doses are required to produce significant dopamine D2 antagonism (Kapur et al., 1998).”
Background(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.9.1089 · Cited by 284 · cited 1×
“Brain imaging studies with computerized tomography in OCD patients showed a volume reduction in the caudate nucleus (Luxenberg et al., 1988).”
BackgroundBehavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis
Kobak, K. A., Greist, J. H., Jefferson, J. W., Katzelnick, D. J., & Henk, H. J. (1998) · Psychopharmacology · doi:10.1007/s002130050558 · Cited by 276
Tek, C., Uluǧ, B., Rezaki, B. G., Tanriverdi, N., Mercan, S., Demir, B., & Vargel, S. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb09801.x · Cited by 147
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adjunctive amisulpride [770] 3 Adjunctive pindolol [774-776] 1*”
Background(2004) · PubMed · Cited by 279
Pharmacotherapy of Obsessive-compulsive Disorder and Obsessive-Compulsive Spectrum Disorders
Denys, D. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.02.013 · Cited by 213
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Neurobiology of Obsessive-Compulsive Disorder:Serotonin and Beyond
Westenberg, H. G. M., Fineberg, N. A., & Denys, D. (2007) · CNS Spectrums · doi:10.1017/s1092852900002479 · Cited by 148
Metadata
- Authors
- Metin, Ö., Yazici, K., Tot, S., & Yazici, A. E.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2003-08
- Volume
- 18
- Issue
- 6
- Pages
- 463-467
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W1982472872
- Cited by
- 68
- References
- 6
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial. https://app.cochat.ai/papers/10.1002/hup.512
- The paper
- Metin, Ö., Yazici, K., Tot, S., & Yazici, A. E. (2003). Amisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.512
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.